Posted by Michael Wonder on 22 Jun 2022
Ikena Oncology receives FDA fast track designation for novel TEAD inhibitor IK-930 to treat unresectable NF2 deficient mesothelioma
22 June 2022 - Ikena Oncology today announced that the U.S. FDA has granted fast track designation for IK-930, the Company’s novel TEAD inhibitor targeting the Hippo signalling pathway, in patients with unresectable NF2 deficient malignant pleural mesothelioma.
IK-930 binds to TEAD transcription factors to prevent transcription of multiple genes in the Hippo pathway that are known to cause cancer progression.
